

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
22		WO	97/17374		05-15-1997	Medac Gesellschaft ...	Pages 18-23	<input type="checkbox"/>
6		WO	05/001038	A2	01-06-2005	Seattle Genetics		

Examiner Signature	<i>M. J. ...</i>	Date Considered	3-30-06
-----------------------	------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/983,340
				Filing Date	November 5, 2004
				First Named Inventor	Doroniia, Svetlana O.
				Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	018891-001020US
Sheet	2	of	2		

*wrong application*  
*4-3-06*

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Blast 2 Sequences Results (2 pages)	
		BARTLETT et al., "Phase I Study of SGN-30, a Chimeric Monoclonal Antibody (mAb), in Patients with Refractory or Recurrent CD30 + Hematologic Malignancies," <u>BLOOD</u> Vol. 100(11), December, 2002, Abs 1403.	
		Safety, Antitumor Activity and Pharmacokinetics of Six Weekly Doses of SGN-30 (anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies," <u>BLOOD</u> 102(11), 2003, Abs 2390.	
		CERVENY et al., "Hodgkin's disease growth inhibition and sensitization to standard chemotherapeutics by the anti-CD30 monoclonal antibody SGN-30," <u>PROC AM ASSOC CANCER RES</u> vol. 45, March 2004, Abs 2258.	
		CERVENY et al., "Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics," <u>LEUKEMIA</u> 19:1648-1655 (2005).	
		CERVENY et al., "The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics," <u>BLOOD</u> 104(11), 2004, Abs 2639	
		KABAT et al., <u>Sequences of Proteins of Immunological Interest</u> , 5th Ed., NIH Publication No. 91-3242, pp. xv-xvi.	
		KOON et al., "Anti-CD30 antibody based therapy," <u>CURRENT OPINION IN ONCOLOGY</u> 12:588-593 (2000)	
		LEONARD et al., "Targeting CD30 as Therapy for Hodgkin's Disease. Phase II Results with the Monoclonal Antibody SGN-30," <u>PROC AM SOC CLIN ONCOL</u> April 2005, Abs 2553	
		LEONARD et al., "Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease," <u>BLOOD</u> 104(11) 2004, Abs 2635.	
		WAHL et al., "The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease," <u>CANCER RES.</u> 62:3736-3742 (2002).	

*Inventor, art unit, docket number  
serial no. none of these matches  
to the instant application.  
my 4-3-06*

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**Complete if Known**

(use as many sheets as necessary)

Sheet	1
-------	---

of

21

Application Number	09/724,406
--------------------	------------

Filing Date	11/28/2000
-------------	------------

First Named Inventor	Francisco et al.
----------------------	------------------

Art Unit	1642
----------	------

Examiner Name	Misook Yu
---------------	-----------

Attorney Docket Number	9632-006-999
------------------------	--------------

## U.S. PATENT DOCUMENTS+


## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**

Date Considered

3-30-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

 <p><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p>					ATTY. DOCKET NO.		APPLICATION NO.	
					9632-006-999		09/724,406	
					APPLICANT			
Francisco et al.				FILING DATE		GROUP		
November 28, 2000				1642				
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES NO	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
my	BM	Bauer et al., 1999, "Immunotherapy of Human Tumors with T-Cell-activating Bispecific Antibodies: Stimulation of Cytotoxic Pathways <i>in Vivo</i> ," Cancer Research, 59:1961-65.						
↓	BN	Pohl et al., 1993, "CD30-Antigen-Specific Targeting and Activation of T Cells Via Murine Bispecific Monoclonal Antibodies Against CD3 and CD28: Potential Use for the Treatment of Hodgkin's Lymphoma," Int. J. Cancer 54:820-27.						
↓	BO	Renner and Pfreundschuh, 1995, "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," Immunology Reviews, 145:178-209.						
EXAMINER <i>Musol 7</i>				DATE CONSIDERED <i>3-20-06</i>				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								

RECEIVED  
 MAR 25 2002  
 TECH CENTER 1600/2800



Express Mail No.: EV 335 857 168 US

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.

9632-006

APPLICATION NO.

09/724,406

APPLICANT

FRANCISCO et al.

CONFIRMATION NO.

7578

FILING DATE

November 28, 2000

GROUP

1642

RECEIVED

OCT 16 2003

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	TECH CENTER SUBCLASS	FILING DATE APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

my	BP	Pohl et al., "CD30-Specific AB1-AB2-AB3 Internal Image Antibody Network: Potential Use as Anti-Idiotypic Vaccine Against Hodgkin's Lymphoma," <i>Int. J. Cancer</i> 54:418-425 (1993)
L	BQ	Weigert et al., "Rearrangement of Genetic Information May Produce Immunoglobulin Diversity," <i>Nature</i> 276:785-790 (1978)

EXAMINER

Misook Y

DATE CONSIDERED

3-20-06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.